Polymorphic form of alcaftadine, composition and process
The present invention relates to novel polymorphic forms of alcaftadine, processes of preparing novel polymorphic forms of alcaftadine and pharmaceutical compositions thereof.
1. An α-crystalline form of alcaftadine having characteristics of X-ray diffraction peaks at 8.3, 10.9, 12.7, 14.7, 15.1, 15.4, 16.0, 16.5, 17.2, 17.7, 18.7, 19.1, 19.9, 21.1, 22.0, 22.7, 24.1, 24.7, 25.1, 26.3, 26.7, 27.2, 28.0, 28.5±0.2 degrees 2θ.
2. A process of preparing an α-crystalline form of alcaftadine comprising the steps of:
a) suspending crude alcaftadine in an organic solvent to obtain a suspension;
b) stirring the suspension obtained in the step of suspending crude alcaftadine; and
c) isolating an α-crystalline form of alcaftadine.
3. The process according to claim 2 , wherein the suspension is stirred at a temperature in the range of 0° to 50° C. for a period of 30 minutes to 6 hours.
4. The process according to claim 2 , wherein the organic solvent is a ketone solvent selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, dibutyl ketone, diethyl ketone, dipropyl ketone, diisopropyl ketone, methyl butyl ketone, methyl propyl ketone, methyl isopropyl ketone, ethyl isopropyl ketone and mixture(s) thereof.
5. The process according to claim 2 , wherein the α-crystalline form of alcaftadine is isolated by the steps of filtration, centrifugation, washing, drying and combinations thereof.
6. The process according to claim 5 , wherein the isolated α-crystalline form of alcaftadine is dried at a temperature in the range of 40° C. to 110° C. for a period of 2 hours to 12 hours under reduced pressure.